<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04052594</url>
  </required_header>
  <id_info>
    <org_study_id>17394</org_study_id>
    <secondary_id>J1T-MC-GZEA</secondary_id>
    <nct_id>NCT04052594</nct_id>
  </id_info>
  <brief_title>A Study of LY3475766 in Healthy Participants</brief_title>
  <official_title>A Randomized, Double-Blind, Single Dose, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3475766</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and tolerability of LY3475766 when given to participants
      with high levels of blood fat called triglycerides. It will also investigate how the body
      processes the study drug and the effect of the study drug on the body. Information about any
      side effects will be documented. This study will last up to 16 weeks for each participant.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline up to Day 85</time_frame>
    <description>A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3475766</measure>
    <time_frame>Predose up to Day 85</time_frame>
    <description>PK: AUC of LY3475766</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Observed Drug Concentration (Cmax) of LY3475766</measure>
    <time_frame>Predose up to Day 85</time_frame>
    <description>PK: Cmax of LY3475766</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Time to Maximum Observed Drug Concentration (Tmax) of LY3475766</measure>
    <time_frame>Predose up to Day 85</time_frame>
    <description>PK: Tmax of LY3475766</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD): Percent Change from Baseline in Triglycerides (TG)</measure>
    <time_frame>Baseline, Day 85</time_frame>
    <description>PD: Percent Change from Baseline in TG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Percent Change from Baseline in Low-Density Lipoprotein Cholesterol (LDL-C)</measure>
    <time_frame>Baseline, Day 85</time_frame>
    <description>PD: Percent Change from Baseline in LDL-C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD: Percent Change from Baseline in Apolipoprotein B (ApoB)</measure>
    <time_frame>Baseline, Day 85</time_frame>
    <description>PD: Percent Change from Baseline in ApoB</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>LY3475766 - IV</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3475766 administered intravenously (IV) to participants with dyslipidemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - IV</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered IV to participants with dyslipidemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LY3475766 - SC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3475766 administered subcutaneously (SC) to participants with dyslipidemia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - SC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC to participants with dyslipidemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3475766 - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>LY3475766 - IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3475766 - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3475766 - SC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - IV</intervention_name>
    <description>Administered IV</description>
    <arm_group_label>Placebo - IV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo - SC</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo - SC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are overtly healthy males or females, apart from dyslipidemia

          -  Male participants must agree to adhere to contraception restrictions

          -  Female participants must be of nonchildbearing potential and include those who are
             infertile due to surgical sterilization or those who are postmenopausal

          -  Have a body mass index (BMI) &gt;18.5 and &lt;40 kilograms per meter squared (kg/m²)

          -  Have clinical laboratory test results within normal reference range, or acceptable
             deviations per investigator discretion

          -  Have a fasting triglyceride (TG) level that is 135 to 499 milligrams per deciliter
             (mg/dL), inclusive, at both screening and Day -1

          -  Have a fasting low density lipoprotein cholesterol (LDL-C) level greater than or equal
             to (≥) 70 mg/dL, inclusive, at screening and Day -1

          -  Have had a stable body weight for the 3 months prior to randomization (&lt;5% body weight
             change)

          -  Have not modified diet or adopted any nutritional lifestyle modification within 3
             months prior to randomization

        Exclusion Criteria:

          -  Are taking or have started taking Proprotein convertase subtilisin/kexin type 9
             (PCSK9) inhibitors within 3 months prior to randomization; or statins, fibrates, or
             niacin ≤1000 mg/day within 8 weeks prior to randomization; or niacin &gt;1000 milligrams
             per day (mg/day) within 16 weeks prior to randomization; or any other lipid-lowering
             agents within 1 month prior to randomization

          -  Are taking or have started taking a beta-blocker, antiarrhythmic, non-dihydropyridine
             calcium channel blocker, ivabradine, or any other heart rate lowering agent within 1
             month or 5 half-lives prior to randomization, whichever is longer

          -  Have a diagnosis of diabetes mellitus (type 1 diabetes mellitus or type 2 diabetes
             mellitus) or have 1 of the following at screening: fasting plasma glucose
             concentration ≥126 mg/dL (7.0 millimoles per liter [mmol/L]) OR a glycated hemoglobin
             level ≥6.5% (48 millimoles per mole [mmol/mol])

          -  Have previously completed or withdrawn from this study or any other study
             investigating LY3475766, and have previously received the investigational product

          -  Have known allergies to LY3475766, related compounds, or any components of the
             formulation, or history of significant atopy

          -  Have a seated heart rate ≤50 beats per minute

          -  Have clinically significant abnormal electrocardiogram (ECG) results constituting a
             risk while taking the investigational product, as determined by the investigator

          -  Have an abnormal blood pressure (BP) as determined by the investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>WCCT Global</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-252-0700</phone>
    </contact>
    <investigator>
      <last_name>David Nguyen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>386-366-6400</phone>
    </contact>
    <investigator>
      <last_name>Hugh A Coleman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75247</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>214-647-9305</phone>
    </contact>
    <investigator>
      <last_name>Jeanelle Kam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>608-443-1471</phone>
    </contact>
    <investigator>
      <last_name>John E Blanchard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 15, 2020</verification_date>
  <study_first_submitted>August 8, 2019</study_first_submitted>
  <study_first_submitted_qc>August 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

